RGLS — Regulus Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $183.30m
- $160.87m
Annual cashflow statement for Regulus Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -18.6 | -15.7 | -27.8 | -28.3 | -30 |
| Depreciation | |||||
| Non-Cash Items | 2.58 | 2.77 | 2.31 | 2.13 | 2.79 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -4.74 | -0.041 | 0.914 | 0.55 | 0.257 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -19.8 | -12.5 | -24.1 | -25.5 | -26.8 |
| Capital Expenditures | -0.221 | 0 | -0.251 | -0.361 | -0.613 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.295 | -0.011 | 0 | -14.8 | 15.1 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Change in Net Intangibles | |||||
| Cash from Investing Activities | 0.074 | -0.011 | -0.251 | -15.1 | 14.5 |
| Financing Cash Flow Items | 40.1 | 18.2 | 32.4 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 39.9 | 9.51 | 53.7 | 4.49 | 11.8 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 20.2 | -3.03 | 29.4 | -36.2 | -0.461 |